Adalimumab-adbm injection, a biosimilar to Humira ® (adalimumab), has been made available by Boehringer Ingelheim. Adalimumab-adbm injection is an interchangeable biosimilar and can be substituted for ...
As widely expected by the pharmaceutical industry, seven pharmaceutical companies are releasing biosimilars of AbbVie's Humira. Boehringer Ingelheim's Cyltezo (adalimumab-adbm), an interchangeable ...
Medicare Part D may cover Humira when a person can self-administer it at home. A person’s Part D costs for Humira will depend on the plan’s formulary and their specific plan. Similarly, Medicare ...
Boehringer Ingelheim, which recently launched the first interchangeable biosimilar to AbbVie’s megablockbuster Humira, is getting in on the industry’s double-pricing trick. After debuting its branded ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback